10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Sponsor
AstraZeneca
Study ID
NCT00997945
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Malignancies

Eligibility Criteria

Sex
MALE
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.

Key Dates

Start date
Oct 31, 2009
Status verified
May 2011
Primary completion
Sep 30, 2010
Completion
Apr 30, 2011

Study Design

Enrollment
15 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: 1
    ZD4054 (Zibotentan) 10mg

Primary Outcome Measure

To assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies [ Time Frame: PK samples will be taken until Day 16 ]

Related Studies